In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Aristoteles Giagounidis discusses the optimal use of lanalidomide as therapy for myelodysplastic syndromes (MDS).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology
© 2017 Imedex, LLC.